| Overview |
| bs-13515R-Cy3 |
| GPR124/TEM5 Polyclonal Antibody, Cy3 Conjugated |
| IF(IHC-P), IF(IHC-F), IF(ICC) |
| Mouse |
| Human, Rat, Dog, Cow, Sheep, Pig, Horse |
| Specifications |
| Cy3 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human G protein coupled receptor 124 |
| 351-450/1338 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 25960 |
| Q96PE1 |
| Cell membrane |
| DKFZp434C211; DKFZp434J0911; FLJ14390; G protein coupled receptor 124; G-protein coupled receptor 124; GP124_HUMAN; GPR 124; GPR124; KIAA1531; TEM 5; TEM5; Tumor endothelial marker 5; Tumor endothelial marker 5 precursor; GPCR GPR124; Adhesion G protein-coupled receptor A2; ADGRA2. |
| Tumor endothelial markers (TEMs) are abundantly expressed in the blood vessels of human solid tumors during angiogenesis and neoangiogensis. These include TEM1 (endosialin), TEM5 (G-protein coupled receptor 124) and TEM7 (plexin domain containing 1). TEMs are associated with the cell surface membrane at low levels in normal human and mouse tissues. TEM5 is a seven-pass transmembrane receptor, whereas TEM1, TEM7 and TEM8 span the membrane once. TEM5 expression is elevated during tumor angiogenesis and neoangiogenesis. TEM7 is highly expressed in tumor endothelium and neurons. Therefore, TEM5 and TEM7 may be suitable targets for the development of antiangiogenic therapies. |
| Application Dilution |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz